Comparison of Four Different Assays for Determination of Serum S-100B

Background: S-100B determination has been shown to be clinically useful in the management of melanoma patients. After the development of a test for determination of the isoforms S100-A1B and S100-BB in serum (S-100B), several sensitive assays for the detection of serum S-100B have become available. We compared four S-100B assays, two automated (LIAISONSangtec100 and ElecsysS100) and two manual ones (Sangtec100 ELISA and CanAg S100 EIA), with respect to clinical data, reference values and correlation. Methods: In a total of 280 samples from 155 melanoma patients and 98 healthy individuals S-100B values were measured simultaneously with the different assays. Results: The inter and intra coefficients of variation were best for the automated assays. The functional sensitivity of both manual assays was 0.15 μg/L. Method comparison revealed satisfactory correlation coefficients of 0.9 or higher, but the slopes ranged from 0.29 to 3.36. Except for the Sangtec100 ELISA, the linearity between the assays was acceptable. The overall sensitivity for melanoma ranged from 37% (ElecsysS100) to 47% (LIAISONSangtec100) and the sensitivity increased with stage. ROC curves showed the best accuracy for the LIAISONSangtec100 assay. Conclusions: All assays gave satisfactory results, but it is advisable to improve the performance of the manual assays for better sensitivity. Agreement about an international reference standard is needed. (Int J Biol Markers 2005; 20: 34-42)

[1]  R. Donato,et al.  Intracellular and extracellular roles of S100 proteins , 2003, Microscopy research and technique.

[2]  G. D. de Gast,et al.  Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma , 2003, Melanoma research.

[3]  C. Heizmann,et al.  S100 proteins: structure, functions and pathology. , 2002, Frontiers in bioscience : a journal and virtual library.

[4]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Hansson,et al.  Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Bonfrer,et al.  Monitoring malignant melanoma with the S-100B tumour marker. , 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[7]  K. Haglid,et al.  A New Specific Method for Measuring S-100B in Serum , 2000, The International journal of biological markers.

[8]  P. Hersey,et al.  Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma. , 1999, Melanoma research.

[9]  A. Hauschild,et al.  S100B Protein Detection in Serum Is a Significant Prognostic Factor in Metastatic Melanoma , 1999, Oncology.

[10]  D. Chan,et al.  Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125. , 1998, Clinical chemistry.

[11]  J. Bonfrer,et al.  Serum S-100 has prognostic significance in malignant melanoma. , 1997, Anticancer research.

[12]  C. Heizmann,et al.  Ca(2+)-binding proteins S100A6 and S100B in primary cutaneous melanoma. , 1997, Journal of cutaneous pathology.

[13]  L. Hansson,et al.  Prognostic value of serum analyses of S‐100β protein in malignant melanoma , 1996 .

[14]  D. Zimmer,et al.  The S100 protein family: History, function, and expression , 1995, Brain Research Bulletin.

[15]  B. Stoffel‐Wagner,et al.  Clinical significance of serum S100 in metastatic malignant melanoma. , 1995, European journal of cancer.

[16]  M. Zweig,et al.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. , 1993, Clinical chemistry.

[17]  C. Laterre,et al.  Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. , 1988, Clinical chemistry.

[18]  W Bablok,et al.  Comparison of Several Regression Procedures for Method Comparison Studies and Determination of Sample Sizes Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part II , 1984, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[19]  W. Bablok,et al.  A New Biometrical Procedure for Testing the Equality of Measurements from Two Different Analytical Methods. Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part I , 1983, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[20]  B. Moore A soluble protein characteristic of the nervous system. , 1965, Biochemical and biophysical research communications.